Income taxes recognized in the income statement (Details 1) - Veraxa Biotech A G [Member] - CHF (SFr) |
12 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Entity Information [Line Items] | ||
| Earnings before income taxes | SFr (67,006,593) | SFr (28,753,745) |
| Income tax expense at a tax rate of 31% | 20,772,044 | 8,913,661 |
| Amortization of deferred tax assets due to derecognition | ||
| Effects of non-tax-deductible expenses and income | (12,336,984) | (5,420,625) |
| Effects of results for which no deferred taxes were recognized | (7,523,688) | (2,666,379) |
| Effects of losses for which deferred tax assets were recognized | ||
| Tax rate differences | (428,768) | (205,883) |
| Tax amount recognized in the income statement | SFr 482,603 | SFr 620,774 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|